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To the Editor:
The long-expected results of the REDUCE trial show that among men 50 to 75 years of age who have prostate-specific antigen (PSA) levels of 2.5 to 10.0 ng per milliliter and who have previously undergone biopsies, the 5α-reductase inhibitor dutasteride significantly reduces the rate of positive biopsies by 23%. The 24.9% rate of positive biopsy results among men who underwent at least two biopsies is consistent with the expressed purpose of the organizers to study a population that had a relatively high risk of prostate cancer. Protocol-mandated biopsies were carried out at year 2 and year 4 during the study. This procedure is in line with clinical practice. Unfortunately, the authors do not address the possibility of avoiding at least some of the 82.8% of negative biopsies. Although the difference in positive biopsies must be considered a very preliminary end point, the possibility that the use of dutasteride avoids unnecessary biopsies must be explored. It has great relevance in a clinical environment, in which the overdiagnosis and overtreatment of prostate cancer are considered to be a major health care problem.
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To the Editor: In the editorial accompanying the article by Andriole et al., Walsh 1 convincingly disproves the conclusion of the REDUCE study, stating that dutasteride does not prevent prostate cancer but merely shrinks tumors. According to Walsh, this holds true for finasteride as well. However, this view cannot provide a post hoc justification for the use of placebo instead of finasteride as a control in the trial of dutasteride therapy. The REDUCE trial was based on the alleged evidence that made finasteride the current standard of treatment -that is, the reported 25% reduction in the risk of prostate cancer 2 -and aimed at showing that dutasteride did as well and possibly better by avoiding the 27% increase with finasteride in less well differentiated tumors that are more likely to be lethal. These expectations were possibly fueled by the fact that, unlike finasteride, dutasteride inhibits both type 1 and type 2 5α-reductase.
How could all this have been proved without a comparison with finasteride? This comparison would have addressed the best interest of patients and national health services but might also have threatened the commercial prospects of dutasteride, which its manufacturer hopes will replace the older but cheaper generic finasteride. To the Editor: Walsh dismisses the value of a reduction in moderately well-differentiated prostate tumors (tumors with a Gleason score of 5 or 6) in the REDUCE trial, suggesting that "many of the tumors were likely to have been clinically insignificant." A diagnosis of cancer, even indolent cancer, is important for the patient. Cancers acquire major clinical significance if they drive radical intervention. And in the United States, 92% of patients who have prostate cancer with a favorable risk receive radical intervention with its attendant complications and effects on quality of life. 1 Even patients who elect the approach of active surveillance acquire the "survivor" label and must deal with the psychological effects of a cancer diagnosis, repeated biopsies, and anxiety about the natural history of their cancer. 2, 3 Modeling of data from the Prostate Cancer Prevention Trial has suggested that the rate of both high-grade and low-grade cancers is reduced by treatment with a 5α-reductase inhibitor. 4 Whether one accepts this or not, the REDUCE study showed that dutasteride therapy, when used as a prevention strategy, will reduce overdiagnosis and hence overtreatment. This is of real value to patients. Laurence Klotz, M.D. have prostate cancer. A large proportion of the negative biopsies in the REDUCE trial were protocol-mandated biopsies; in clinical practice, dutasteride should result in the need for fewer biopsies because it suppresses PSA production from benign tissue (and indolent prostate cancers), as seen in two previous studies. 1,2 Data from the REDUCE trial showed that although rising PSA levels were a poor predictor of overall cancer and of high-grade cancer in the placebo group (perhaps since many placebo-treated men had rising PSA levels as a result of benign prostatic hyperplasia), rising PSA levels were a strong predictor of tumors with Gleason scores of 7 to 10 in the dutasteride group. The effect of dutasteride on the usefulness of PSA level for the diagnosis of prostate cancer would be the subject of a separate article. Garattini and Bertele' question why placebo (rather than finasteride) was chosen for comparison with dutasteride and whether the data from the REDUCE trial can help determine whether inhibition of both isoforms of 5α-reductase by dutasteride is superior to the inhibition of only one isoform by finasteride (as studied in the Prostate Cancer Prevention Trial). Finasteride was not used in the REDUCE trial for three main reasons: finasteride is not an approved therapy for reducing the risk of prostate cancer, the REDUCE trial was initiated before the results of the Prostate Cancer Prevention Trial were reported, and the reduction in the risk of prostate cancer with finasteride has never been tested in the population studied in the REDUCE trial (men with elevated PSA levels). Increased type 1 5α-reductase in prostate tumors, especially in high-grade tumors, provides a biologically based rationale for the use of a dual inhibitor of 5α-reductase to achieve a reduction in the risk of prostate cancer 3 ; however, the REDUCE trial was not designed to test this hypothesis directly. In a prespecified analysis of data from the REDUCE trial in which baseline predictors of prostate cancer and postbaseline prostate volume at the time of biopsy were incorporated into the model (see the Supplementary Appendix, available with the full text of the article at NEJM.org), the odds ratio for prostate cancer, detected on biopsy, with dutasteride as compared with placebo was 0.60 for all tumors (95% confidence interval [CI] , 0.52 to 0.68; P<0.001) and 0.62 for tumors with Gleason scores of 7 to 10 (95% CI, 0.49 to 0.79; P = 0.001). The editorialist replies: Garattini and Bertele' argue that a direct comparison is necessary to determine whether dutasteride is equivalent to finasteride. I believe that such a study is unlikely to show any difference, because inhibition of the type 1 5α-reductase isoform does not appear to provide significant additional benefit. The relative reduction in the risk of a positive biopsy with either agent is 23 to 25%, and among men who underwent random biopsies without a cause, there was neither a decrease nor an increase in the risk of prostate tumors with Gleason scores of 7 to 10. Klotz misunderstands the clinical implications of the study. All the participants underwent random biopsies. However, dutasteride reduced the risk of cancer only in men who would never have known that they had cancer and who would not have received treatment because in a clinical setting they would never have undergone a biopsy. These were men with one or two previous negative biopsies who had been screened for more than 2 to 4 years and had no clinical indication for a biopsy. In contrast, among men with an indication for a biopsy (abnormal digital rectal examination or PSA level corrected for the effect of the drug), treatment with dutasteride failed to decrease the risk of cancer. Because treatment with dutasteride produces a marked reduction in PSA levels, men may be lulled into a false sense of security. They will interpret this reduction as they understand the effect of statins in lowering cholesterol ("My PSA is down by 50%; now I don't have to worry about prostate cancer") without
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understanding that the decrease in PSA level is only the result of shrinkage of benign prostatic tissue. For this reason, dutasteride may delay the diagnosis of prostate cancer until a patient has high-grade disease that may be difficult to cure. As was concluded in another publication, "in clinical practice taking dutasteride would probably decrease the number of prostate biopsies and subsequent radiation treatments and prostatectomies, but it might also increase the number of deaths from the disease." 1 Rather than advising the use of a drug that could be dangerous and costs $1,500 per year, if Dr. Klotz wishes to reduce the overdiagnosis and overtreatment of prostate cancer, why not simply discourage PSA testing? Patrick C. Walsh, M.D.
